https://insight.jci.org/articles/view/157342
Disulfiram inhibits neutrophil extracellular trap formation protecting rodents from acute lung injury and SARS-CoV-2 infection
Published February 8, 2022 – More info
Disulfiram has previously been associated in observational studies with lowering the risk of infection from SARS-CoV-2, and one study of the drug in human patients with moderate COVID-19 was completed in 2021, but results haven’t yet been posted. A separate trial testing the drug against COVID-19 in humans has not yet been completed.
For more:
- https://madisonarealymesupportgroup.com/2020/12/22/evaluation-of-disulfiram-drug-combinations-identification-of-other-more-effective-combinations-against-stationary-phase-borrelia-burgdorferi/
- https://madisonarealymesupportgroup.com/2019/11/19/if-disulfiram-is-the-cure-for-lyme-disease-should-it-be-prescribed-to-all-lyme-disease-patients/
- https://madisonarealymesupportgroup.com/2020/12/07/repurposing-disulfiram-in-the-treatment-of-lyme-disease-and-babesiosis-retrospective-review-of-first-3-years-experience-in-one-medical-practice/
- https://madisonarealymesupportgroup.com/2020/11/30/patients-can-respond-very-differently-to-disulfiram-be-cautious/
- https://madisonarealymesupportgroup.com/2019/10/15/disulfiram-psychosis-update/
- https://madisonarealymesupportgroup.com/2019/10/27/disulfiram-psychosis-update-2/
Other drugs approved for different uses have shown some success against COVID-19, including ivermectin, hydroxychloroquine, and fluvoxamine, though U.S. health officials primarily recommend ones such as paxlovid that are specifically approved.